

#### **CAWC Events**

# 15th Annual CAWC Conference

Quebec City, QC October 29— November 1, 2009 Visit www.cawc.net. See page 56 for details.

# 15<sup>e</sup> Congrès annuel de l'ACSP

Ville de Québec, PQ 29 octobre – 1 novembre 2009 Veuillez visiter www.cawc.net. Veuillez voir la page 56 pour les détails.

#### **Other Events**

## 22nd Annual Symposium on Advanced Wound Care and Wound Healing Society Meeting

April 26-29, 2009 Gaylord Texan Hotel and Convention Center Dallas, TX www.sawc.net

## Canadian Association for Enterostomal Therapy 28th Annual Conference

May 27-30, 2009 Delta Regina Hotel Regina, SK

### Wound, Ostomy and Continence Nurses Society 41st Annual Conference

June 6-10, 2009 St. Louis Convention Center St. Louis, MO www.wocn.org

#### **Industry News**

#### Introducing Systagenix Wound Management: A New Global Force in Advanced Wound Care

Systagenix Wound Management was established in December 2008 by One Equity Partners to acquire the Wound Care Business of Johnson & Johnson (J&J). Systagenix recognized the value of the internationally renowned J&J wound-careproduct portfolio and will continue to build upon that reputation. This portfolio includes trusted brands such as PROMOGRAN® Matrix Wound Dressing, TIELLE® Hydropolymer Dressing, and REGRANEX® (becaplermin) Gel 0.01%. Systagenix is committed to providing innovative products that help enhance the quality of life of patients. The organization promises to be a new global force in advanced wound care.

#### Overview of Coloplast

Coloplast is highly regarded around the world for developing innovative products for people with ostomy, urology, continence, chronic wound and skin needs. For example, the company developed the world's first disposable ostomy bag. Coloplast's key focal areas include ostomy care, urology and continence care, dressings for chronic wounds and skin-care products. Key brands include Biatain, Biatain Ag, Biatain Ibu, SeaSorb Ag, Comfeel, Assura, InterDry, Sween, SenSura, SpeediCath, Titan, Aris, Self Cath and Freedom. With headquarters in Denmark, the United States and Canada, the company is a global force in products and services for people with intimate health-care needs. For more information about Coloplast, please visit www.coloplast.ca.

# ArjoHuntleigh Focuses on Service

For over 40 years, ArjoHuntleigh has been assisting people with reduced mobility. The company's philosophy of "with people in mind" reinforces its dedication to delivering quality products and programs that reduce the risks to patients, residents and

caregivers, and provide returns for hospitals and care homes. Service is key at ArjoHuntleigh. In fact, the company is one of the most comprehensive service organizations in Canada. This ensures that equipment is always available when needed. For more information about ArjoHuntleigh beds, mattresses and lifts, please visit www.arjohuntleigh.com.

#### New Ribbon Hydrofiber® Dressings at ConvaTec

ConvaTec is proud to inform you that the new AQUACEL® and AQUACEL® Ag dressings with Strengthening Fiber are now available. These new dressings will replace the original AQUACEL® and AQUACEL® Ag Ribbon Dressings. They have all the advantages of the original dressings with the addition of stitch bonding to strengthen them.1 These dressings are over 20 times stronger\* and have more than 1.3 times less shrinkage.\* Questions? Please contact the ConvaTec Customer Relations Center at 1-800-465-6302.

- \*Compared with the original AQUACEL\* and AQUACEL\* Ag dressings
- 1. ConvaTec. Data on File. WHRI 3178 TA 155. 8 October 2008.

All Industry News is supplied by the companies or their agencies and is published as a courtesy by the CAWC.



When you see the Web Connect icon associated with an article, look for more information on the CAWC Web site at www.cawc.net. Click on *Wound Care Canada*.





# The only NPWT with over 400 peer-reviewed journal articles.

When you need confidence in your wound healing outcomes, choose the only NPWT with 400 peer-reviewed journal articles, 461 abstracts, 61 textbook citations, 15 RCTs and thousands of case studies from the more than 2,800,000 patients treated to date.

